Luis J Montaner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/382593/publications.pdf

Version: 2024-02-01

52 2,753 23 50 papers citations h-index g-index

57 57 57 57 4411

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: Review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts. Journal of Leukocyte Biology, 2020, 108, 17-41.	3.3	573
2	Persistent Decreases in Blood Plasmacytoid Dendritic Cell Number and Function Despite Effective Highly Active Antiretroviral Therapy and Increased Blood Myeloid Dendritic Cells in HIV-Infected Individuals. Journal of Immunology, 2002, 168, 4796-4801.	0.8	309
3	Pegylated Interferon Alfa-2a Monotherapy Results in Suppression of HIV Type 1 Replication and Decreased Cell-Associated HIV DNA Integration. Journal of Infectious Diseases, 2013, 207, 213-222.	4.0	183
4	Recommendations for analytical antiretroviral treatment interruptions in HIV research trials—report of a consensus meeting. Lancet HIV,the, 2019, 6, e259-e268.	4.7	139
5	Enhancement of Human Immunodeficiency Virus Type 1–Specific CD4 and CD8 T Cell Responses in Chronically Infected Persons after Temporary Treatment Interruption. Journal of Infectious Diseases, 2000, 182, 766-775.	4.0	108
6	Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nature Communications, 2021, 12, 346.	12.8	107
7	CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells. Science Translational Medicine, 2018, 10, .	12.4	105
8	Distinct Populations of Immune-Suppressive Macrophages Differentiate from Monocytic Myeloid-Derived Suppressor Cells in Cancer. Cell Reports, 2020, 33, 108571.	6.4	99
9	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. Nature Medicine, 2020, 26, 1339-1350.	30.7	96
10	Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN). Clinical and Experimental Immunology, 2011, 164, 158-169.	2.6	79
11	Baseline Viral Load and Immune Activation Determine the Extent of Reconstitution of Innate Immune Effectors in HIV-1-Infected Subjects Undergoing Antiretroviral Treatment. Journal of Immunology, 2007, 179, 2642-2650.	0.8	75
12	Randomized, Controlled Trial of Therapy Interruption in Chronic HIV-1 Infection. PLoS Medicine, 2004, 1, e64.	8.4	67
13	Intact proviral DNA assay analysis of large cohorts of people with HIV provides a benchmark for the frequency and composition of persistent proviral DNA. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 18692-18700.	7.1	67
14	Anti-α4β7 therapy targets lymphoid aggregates in the gastrointestinal tract of HIV-1–infected individuals. Science Translational Medicine, 2018, 10, .	12.4	65
15	Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption. Science Translational Medicine, 2021, 13, .	12.4	54
16	NK Cell Lysis of HIV-1-Infected Autologous CD4 Primary T Cells: Requirement for IFN-Mediated NK Activation by Plasmacytoid Dendritic Cells. Journal of Immunology, 2007, 179, 2097-2104.	0.8	50
17	Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 32066-32077.	7.1	44
18	The role of CD32 during HIV-1 infection. Nature, 2018, 561, E17-E19.	27.8	43

#	Article	IF	CITATIONS
19	Increased plasmacytoid dendritic cell maturation and natural killer cell activation in HIV-1 exposed, uninfected intravenous drug users. Aids, 2010, 24, 2151-2160.	2.2	33
20	CCR5 and CXCR4 expression correlated with X4 and R5 HIV-1 infection yet not sustained replication in Th1 and Th2 cells. Aids, 2001, 15, 1941-1949.	2.2	31
21	Non-invasive plasma glycomic and metabolic biomarkers of post-treatment control of HIV. Nature Communications, 2021, 12, 3922.	12.8	31
22	HIV-1-negative female sex workers sustain high cervical IFNÉ>, low immune activation, and low expression of HIV-1-required host genes. Mucosal Immunology, 2016, 9, 1027-1038.	6.0	28
23	Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. Aids, 2020, 34, 681-686.	2.2	26
24	The Natural Stilbenoid ($\hat{a}\in$ ")-Hopeaphenol Inhibits Cellular Entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7, and B.1.351 Variants. Antimicrobial Agents and Chemotherapy, 2021, 65, e0077221.	3.2	26
25	Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells. Aids, 2007, 21, 293-305.	2.2	25
26	Innate Activation of MDC and NK Cells in High-Risk HIV-1–Exposed Seronegative IV-Drug Users Who Share Needles When Compared With Low-Risk Nonsharing IV-Drug User Controls. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 264-273.	2.1	23
27	Intact Human Immunodeficiency Virus (HIV) Reservoir Estimated by the Intact Proviral DNA Assay Correlates With Levels of Total and Integrated DNA in the Blood During Suppressive Antiretroviral Therapy. Clinical Infectious Diseases, 2021, 72, 495-498.	5. 8	23
28	Retention of viability, cytotoxicity, and response to IL-2, IL-15, or IFN- \hat{l}_{\pm} by human NK cells after CD107a degranulation. Journal of Leukocyte Biology, 2009, 85, 871-876.	3.3	22
29	IFN-α augments natural killer-mediated antibody-dependent cellular cytotoxicity of HIV-1-infected autologous CD4+ T cells regardless of major histocompatibility complex class 1 downregulation. Aids, 2017, 31, 613-622.	2.2	22
30	BCL6 represses antiviral resistance in follicular T helper cells. Journal of Leukocyte Biology, 2017, 102, 527-536.	3.3	21
31	A Correlate of HIV-1 Control Consisting of Both Innate and Adaptive Immune Parameters Best Predicts Viral Load by Multivariable Analysis in HIV-1 Infected Viremic Controllers and Chronically-Infected Non-Controllers. PLoS ONE, 2014, 9, e103209.	2.5	17
32	NK Response Correlates with HIV Decrease in Pegylated IFN-α2a–Treated Antiretroviral Therapy–Suppressed Subjects. Journal of Immunology, 2019, 203, 705-717.	0.8	16
33	Quantitation of Integrated HIV Provirus by Pulsed-Field Gel Electrophoresis and Droplet Digital PCR. Journal of Clinical Microbiology, 2018, 56, .	3.9	15
34	Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption. MBio, 2021, 12, .	4.1	15
35	A20 upregulation during treated HIV disease is associated with intestinal epithelial cell recovery and function. PLoS Pathogens, 2018, 14, e1006806.	4.7	12
36	BCL6 Inhibitor-Mediated Downregulation of Phosphorylated SAMHD1 and T Cell Activation Are Associated with Decreased HIV Infection and Reactivation. Journal of Virology, 2019, 93, .	3 . 4	11

#	Article	IF	CITATIONS
37	Plasmacytoid dendritic cell and functional <scp>HIV</scp> Gag p55â€specific T cells before treatment interruption can inform setâ€point plasma <scp>HIV</scp> viral load after treatment interruption in chronically suppressed <scp>HIV</scp> â€1 ⁺ patients. Immunology, 2015, 145, 380-390.	4.4	10
38	Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. Journal of Leukocyte Biology, 2016, 100, 223-231.	3.3	10
39	Serial Cervicovaginal Exposures With Replication-Deficient SIVsm Induce Higher Dendritic Cell (pDC) and CD4+ T-Cell Infiltrates Not Associated With Prevention but a More Severe SIVmac251 Infection of Rhesus Macaques. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, 405-413.	2.1	9
40	Effect of Opioid Use on Immune Activation and HIV Persistence on ART. Journal of NeuroImmune Pharmacology, 2020, 15, 643-657.	4.1	9
41	HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapyâ€treated HIV/HCVâ€coâ€infected subjects. Journal of Viral Hepatitis, 2017, 24, 865-876.	2.0	8
42	BCL6 BTBâ€specific inhibitor reversely represses Tâ€cell activation, Tfh cells differentiation, and germinal center reaction in vivo. European Journal of Immunology, 2021, 51, 2441-2451.	2.9	6
43	Preliminary Acceptability of a Home-Based Peripheral Blood Collection Device for Viral Load Testing in the Context of Analytical Treatment Interruptions in HIV Cure Trials: Results from a Nationwide Survey in the United States. Journal of Personalized Medicine, 2022, 12, 231.	2.5	6
44	S100A14 Is Increased in Activated NK Cells and Plasma of HIV-Exposed Seronegative People Who Inject Drugs and Promotes Monocyte–NK Crosstalk. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 234-241.	2.1	5
45	Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women. Carcinogenesis, 2019, 40, 225-233.	2.8	5
46	BCL6 BTBâ€specific inhibition via FX1 treatment reduces Tfh cells and reverses lymphoid follicle hyperplasia in Indian rhesus macaque (Macaca mulatta). Journal of Medical Primatology, 2020, 49, 26-33.	0.6	5
47	Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption. Journal of Virology, 2021, 95, .	3.4	5
48	Use of hyphenated analytical techniques to identify the bioactive constituents of Gunnera perpensa L., a South African medicinal plant, which potently inhibit SARS-CoV-2 spike glycoprotein–host ACE2 binding. Analytical and Bioanalytical Chemistry, 2022, 414, 3971-3985.	3.7	5
49	Repeated semen exposure decreases cervicovaginal SIVmac251 infection in rhesus macaques. Nature Communications, 2019, 10, 3753.	12.8	3
50	Persons who inject drugs (PWID) retain functional NK cells, dendritic cell stimulation, and adaptive immune recall responses despite prolonged opioid use. Journal of Leukocyte Biology, 2021, 110, 385-396.	3.3	3
51	Hepatitis C virus modulates IgG glycosylation in HIV co-infected antiretroviral therapy suppressed individuals. Aids, 2020, 34, 1461-1466.	2.2	2
52	The Minority Scientists' Experience: Challenging and Overcoming Barriers to Enhancing Diversity and Career Advancement. Journal of Immunology, 2022, 208, 197-202.	0.8	2